Moneycontrol PRO
Upcoming Webinar:Watch Kushal Bhagi of Tortuga Wealth Managers decode how you can maximise your MF investments on Sept 21 @11am. Register Now

Subscribe to Tatva Chintan Pharma Chem: Anand Rathi

Anand Rathi has come out with its report on Tatva Chintan Pharma Chem. The research firm has recommended to ''Subscribe'' the ipo in its research report as on July 15, 2021.

July 16, 2021 / 01:53 PM IST
  • bselive
  • nselive
Todays L/H

Anand Rathi IPO report on Tatva Chintan Pharma Chem

Tatva Chintan Pharma Chem Ltd is a specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of Structure Directing Agent (SDAs), Phase Transfer Catalyst (PTCs), electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC). The Company is the largest and only commercial manufacturer of SDAs for zeolites in India. It also enjoys the second largest position globally. As of March 31, 2021, The Company have offered 47 products under their SDA product portfolio, 48 products under the PTC product portfolio, 6 products under the electrolyte salts for super capacitor batteries portfolio and 53 products under their PASC portfolio.

Valuation and Outlook

We are positive on the long-term prospects of the Company. Hence, we recommend a "Subscribe" rating to this IPO.

For all IPO stories, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark